Back to top
more

ZIOPHARM Oncology Inc (ZIOP)

(Delayed Data from NSDQ)

$4.68 USD

4.68
2,043,608

+0.19 (4.23%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Alaunos Therapeutics, Inc. [ZIOP]

Reports for Purchase

Showing records 1 - 20 ( 120 total )

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

11/15/2021

Company Report

Pages: 6

TCR-T Library Study Slated to Start in 1H22; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ZIOP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/17/2021

Company Report

Pages: 7

Progress with TCR-T Library Program; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/10/2021

Company Report

Pages: 6

Awaiting Initial Data From Clinical Programs in 2H21; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/01/2021

Company Report

Pages: 6

Awaiting Clarity on Management and Pipeline Reshuffle; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

11/09/2020

Company Report

Pages: 7

Controlled IL-12 Data Updates at SNO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

08/07/2020

Company Report

Pages: 6

GBM Data Updates Expected at SNO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

06/02/2020

Daily Note

Pages: 5

Positive rGBM Data Readouts at ASCO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

05/11/2020

Company Report

Pages: 7

Mitigating COVID-19 Impacts; GBM Data at ASCO; Lower $5.50PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/03/2020

Company Report

Pages: 6

Eventful 1H20 Expected; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/10/2019

Daily Note

Pages: 4

RPM?s Potential in TCR Cell Therapy Validated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/08/2019

Company Report

Pages: 7

Expanded MDA Collaboration; TCR and CAR-T Studies Ready to Begin; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

10/02/2019

Daily Note

Pages: 3

Rapid Manufactured CAR-T Receives IND Clearance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/09/2019

Company Report

Pages: 7

Strong Progress Across Multiple Clinical Programs; Higher $6.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

05/09/2019

Company Report

Pages: 7

Pipeline Expansion Continues With Clinical Updates at ASCO in June; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/06/2019

Company Report

Pages: 6

POC CAR-T Program Moving Forward; New Clinical Studies Ready; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/20/2018

Daily Note

Pages: 3

New Collaboration to Bring POC CAR-T to China; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/13/2018

Company Report

Pages: 7

Collaboration With Regeneron in GBM; Update at SNO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

10/10/2018

Daily Note

Pages: 3

Intrexon Agreement Revised to Focus on IL-12 and TCR; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Alaunos Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/07/2018

Daily Note

Pages: 6

We are Suspending Coverage on the following companies due to analyst transition

Provider: Griffin Securities, Inc.

Price: 25.00

Research Provided by a Third Party
// eof